FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376641456> ?p ?o ?g. }

• W4376641456 endingPage "302" @default.
• W4376641456 startingPage "291" @default.
• W4376641456 abstract "Lung cancer is the most common malignancy in the world and the leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive non-small cell lung cancer (NSCLC) refers to the NSCLC caused by mutation, amplification or overexpression of the HER2 gene, resulting in its dysfunction. HER2 is the most active receptor in the HER family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. In NSCLC, HER2 positivity is usually considered a poor prognostic marker. At present, the diagnosis and treatment of HER2-positive NSCLC are not mature. Immunohistochemistry (IHC), next generation sequencing (NGS) and other technologies are often used to detect the positive status of HER2 mutation, amplification or overexpression. In previous studies, antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC. However, in recent years, related researches have shown that antibody-drug conjugates (ADCs) and new tyrosine kinase inhibitors (TKIs) in targeted therapy show good antitumor activity against HER2 positive NSCLC. This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches. .【中文题目：HER2阳性非小细胞肺癌诊断及治疗进展】 【中文摘要：肺癌是全球最常见的恶性肿瘤，也是癌症死亡的主要原因。人表皮生长因子受体2（human epidermal growth factor receptor 2, HER2）阳性非小细胞肺癌（non-small cell lung cancer, NSCLC）是指因HER2基因发生突变、扩增、过表达，导致其功能失调，从而发生的NSCLC。HER2是HER家族中活性最高的受体，可以与其他成员结合形成二聚体，激活多种信号通路，从而调节细胞增殖、分化、迁移和凋亡。在NSCLC中，HER2阳性通常被认为是预后不良的标志。目前HER2阳性NSCLC的诊疗尚未成熟。通常使用免疫组化（immunohistochemistry, IHC）、下一代测序（next generation sequencing, NGS）等方法来检测HER2突变、扩增、过表达这些阳性状态。在先前的研究中，抗肿瘤药物在HER2阳性NSCLC中并未显示出理想的疗效。但近些年来，相关研究表明靶向治疗中的抗体药物偶联物（antibody-drug conjugates, ADCs）和新型酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）对HER2阳性NSCLC显示出较好的抗肿瘤活性。本文归纳了HER2阳性NSCLC的诊断和治疗进展，为后续研究提供参考。 】 【中文关键词：肺肿瘤；人表皮生长因子受体2；靶向治疗】." @default.
• W4376641456 created "2023-05-17" @default.
• W4376641456 creator A5009863367 @default.
• W4376641456 creator A5022844889 @default.
• W4376641456 creator A5032415345 @default.
• W4376641456 creator A5038304189 @default.
• W4376641456 creator A5059554446 @default.
• W4376641456 date "2023-04-20" @default.
• W4376641456 modified "2023-10-16" @default.
• W4376641456 title "[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer]." @default.
• W4376641456 cites W1984007340 @default.
• W4376641456 cites W2082664617 @default.
• W4376641456 cites W2101979288 @default.
• W4376641456 cites W2107562400 @default.
• W4376641456 cites W2112854176 @default.
• W4376641456 cites W2129750399 @default.
• W4376641456 cites W2159192794 @default.
• W4376641456 cites W2175694606 @default.
• W4376641456 cites W2314772071 @default.
• W4376641456 cites W2735084022 @default.
• W4376641456 cites W2783112448 @default.
• W4376641456 cites W2799596353 @default.
• W4376641456 cites W2800964883 @default.
• W4376641456 cites W2801651204 @default.
• W4376641456 cites W2806209829 @default.
• W4376641456 cites W2807519281 @default.
• W4376641456 cites W2885615830 @default.
• W4376641456 cites W2889646458 @default.
• W4376641456 cites W2889957730 @default.
• W4376641456 cites W2896602377 @default.
• W4376641456 cites W2907907709 @default.
• W4376641456 cites W2910011825 @default.
• W4376641456 cites W2913258427 @default.
• W4376641456 cites W2915968104 @default.
• W4376641456 cites W2977889895 @default.
• W4376641456 cites W2990223332 @default.
• W4376641456 cites W2993982684 @default.
• W4376641456 cites W3000445801 @default.
• W4376641456 cites W3010457537 @default.
• W4376641456 cites W3013150216 @default.
• W4376641456 cites W3013632168 @default.
• W4376641456 cites W3037442044 @default.
• W4376641456 cites W3038770224 @default.
• W4376641456 cites W3043420774 @default.
• W4376641456 cites W3115703756 @default.
• W4376641456 cites W3120155456 @default.
• W4376641456 cites W3148715585 @default.
• W4376641456 cites W3159002307 @default.
• W4376641456 cites W3170003796 @default.
• W4376641456 cites W3177593112 @default.
• W4376641456 cites W3187778387 @default.
• W4376641456 cites W3198587100 @default.
• W4376641456 cites W3200524238 @default.
• W4376641456 cites W3201219318 @default.
• W4376641456 cites W3213434965 @default.
• W4376641456 cites W3214033827 @default.
• W4376641456 cites W3216736267 @default.
• W4376641456 cites W3216934409 @default.
• W4376641456 cites W4200038491 @default.
• W4376641456 cites W4210484120 @default.
• W4376641456 cites W4210935856 @default.
• W4376641456 cites W4214818973 @default.
• W4376641456 cites W4220952874 @default.
• W4376641456 cites W4221089418 @default.
• W4376641456 cites W4223935840 @default.
• W4376641456 cites W4282977105 @default.
• W4376641456 cites W4293511064 @default.
• W4376641456 cites W4293659721 @default.
• W4376641456 cites W4306250654 @default.
• W4376641456 cites W4318204989 @default.
• W4376641456 doi "https://doi.org/10.3779/j.issn.1009-3419.2023.102.14" @default.
• W4376641456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37183644" @default.
• W4376641456 hasPublicationYear "2023" @default.
• W4376641456 type Work @default.
• W4376641456 citedByCount "0" @default.
• W4376641456 crossrefType "journal-article" @default.
• W4376641456 hasAuthorship W4376641456A5009863367 @default.
• W4376641456 hasAuthorship W4376641456A5022844889 @default.
• W4376641456 hasAuthorship W4376641456A5032415345 @default.
• W4376641456 hasAuthorship W4376641456A5038304189 @default.
• W4376641456 hasAuthorship W4376641456A5059554446 @default.
• W4376641456 hasConcept C121608353 @default.
• W4376641456 hasConcept C126322002 @default.
• W4376641456 hasConcept C143998085 @default.
• W4376641456 hasConcept C170493617 @default.
• W4376641456 hasConcept C204232928 @default.
• W4376641456 hasConcept C2776256026 @default.
• W4376641456 hasConcept C2778807442 @default.
• W4376641456 hasConcept C2779399171 @default.
• W4376641456 hasConcept C2779438470 @default.
• W4376641456 hasConcept C2779786085 @default.
• W4376641456 hasConcept C2781230642 @default.
• W4376641456 hasConcept C42362537 @default.
• W4376641456 hasConcept C502942594 @default.
• W4376641456 hasConcept C530470458 @default.
• W4376641456 hasConcept C71924100 @default.
• W4376641456 hasConceptScore W4376641456C121608353 @default.
• W4376641456 hasConceptScore W4376641456C126322002 @default.

• next